bipolar disorder

8560840624_7452a42f5e_k

Introduction

Bipolar, otherwise known as manic depression, now exists largely within common consciousness and understanding, thanks to high profile stigma-busting publicity.

Characterised by episodic shifts in a person’s mood (between manic and depressed states), as well as their energy and activity levels, which can significantly impact their daily functioning, bipolar is estimated to affect 1% of the population across the lifetime. However, this figure rises to over 4% if you include those who experience more than one episode of sub-threshold manic (or ‘hypomanic’) symptoms.

What we know already

Anxiety is unsurprisingly common in people living with bipolar. Similarly, substance abuse is frequently reported.

Whilst there is no cure, there are several well-established treatment options. Bipolar is usually treated using mood-stabiliser, atypical anti-psychotic and/or antidepressant medications, alongside psychological, and diet and lifestyle interventions. We know, for example, that bipolar can be well managed using regular monitoring of mood, keeping stress levels to a minimum, and ensuring good sleep.

Areas of uncertainty 

Like many mental health difficulties, the precise causes of bipolar are unknown, though they are likely multi-faceted. Research shows that you are more likely to develop bipolar if it exists in your family. Although most children with such circumstances will not go on to develop bipolar, there appears to be a strong genetic component. Environmental factors such as stressful life events are also thought to play an important role.

Recent research suggests that, whilst it appears beneficial to treat bipolar with psychological interventions, the heterogeneity of the evidence makes it difficult to decide which treatments (such as CBT, Mindfulness etc) work best.

What’s in the pipeline?

Large-scale studies, such as the U.S-based Bipolar Disorder Phenome Database, are seeking to better understand the complex genetic picture.

Advances in brain imaging will no doubt provide rich information regarding the neurochemical and neurostructural profile of bipolar. Similarly, technological advances are enabling more sophisticated ways of promoting self-management in conditions such as bipolar.

References

Merikangas, K.R., Akiskal, H.S., Angst, J., et al. (2007) Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Archives of General Psychiatry, 64, 543-552. [Abstract]

Stratford, H.J., Cooper, M.J., Di Simplicio, M., Blackwell, S.E. and Holmes, E.A. (2015) Psychological therapy for anxiety in bipolar spectrum disorders: a systematic review. Clinical Psychology Review, 35, 19-34. [Abstract]

Acknowledgement

Written by: Patrick Kennedy-Williams
Reviewed by:
Last updated: Sep 2015
Review due: Sep 2016

Our bipolar disorder Blogs

Young men with bipolar disorder are more likely to drop out from online psycho-education programmes

iStock_000016115404XSmall bored depressed young man with laptop

Web-based education support for people with health problems is now widespread, but there is comparatively little research that explores the reasons why people do not complete online courses once they are enrolled. This paper presents data from a randomised controlled trial based in Australia, where 370 participants were randomly allocated to: An online bipolar education [read the full story…]

Lithium is a better treatment for bipolar disorder than valproate

iStock_000016388795XSmall round blue pills bottle

Valproate is widely used as a mood stabiliser for people with bipolar disorder, despite the fact that there is very little evidence that shows the effectiveness of this treatment. This observational cohort study looked at over 4,000 bipolar patients in Denmark who were treated with lithium or valproate from 1995 to 2006. The results favoured [read the full story…]

NICE likely to update guidance on bipolar disorder & antenatal and postnatal mental health

nhs evidence eye

The National Institute for Health and Clinical Excellence (NICE) is undertaking a review to decide whether the NICE clinical guidelines on bipolar disorder (CG38) and antenatal and postnatal mental health (CG45) should be updated. Within the review proposal consultation document, NICE has concluded that the guidelines should be considered for an update at this time. The [read the full story…]

People with schizophrenia and bipolar disorder have a much lower life expectancy

Pen and statistical information

A recently published study conducted at the Maudsley Hospital has reported that people with schizophrenia and bipolar disorder have a life expectancy of 10-15 years lower than the UK average. Researchers looked at the electronic medical records of more than 30,000 patients suffering from severe mental health problems. They found that many patients were dying [read the full story…]

Aripiprazole: maintenance treatment for bipolar disorder. Where’s the evidence?

Aripiprazole

Aripiprazole is a second-generation antipsychotic that is widely used as a maintenance treatment for bipolar disorder in the US. It was approved by the FDA as a drug for this purpose in 2005. A new systematic review, published in the online journal PLOS medicine, sought to critically review the evidence supporting the use of aripiprazole [read the full story…]